Notify me when Camber Capital Management LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
|---|---|---|---|---|---|---|---|---|
| Q2 2025 | 23 | $718M | +$135M | -$916M | -$782M | ZBH, BAX, HUM, CVS, GMED | 13F-HR | 8/14/2025, 04:11 PM |
| Q1 2025 | 28 | $1.6B | +$212M | -$1.15B | -$938M | ZBH, BAX, HUM, CVS, GMED | 13F-HR | 5/15/2025, 04:17 PM |
| Q4 2024 | 36 | $2.56B | +$600M | -$393M | +$206M | MDT, VTRS, ZBH, HUM, PTCT | 13F-HR | 2/14/2025, 08:58 AM |
| Q3 2024 | 32 | $2.57B | +$459M | -$628M | -$170M | ZBH, MDT, BAX, VTRS, GMED | 13F-HR | 11/14/2024, 09:41 AM |
| Q2 2024 | 35 | $2.59B | +$479M | -$608M | -$129M | ZBH, BAX, MDT, UHS, GMED | 13F-HR | 8/14/2024, 09:28 AM |
| Q1 2024 | 34 | $2.86B | +$314M | -$608M | -$294M | ZBH, UHS, BAX, THC, VTRS | 13F-HR | 5/15/2024, 08:48 AM |
| Q4 2023 | 36 | $2.86B | +$445M | -$623M | -$179M | UHS, THC, ZBH, VTRS, BAX | 13F-HR | 2/14/2024, 08:18 AM |
| Q3 2023 | 39 | $2.79B | +$438M | -$378M | +$60.3M | UHS, THC, ZBH, VTRS, SNY | 13F-HR | 11/14/2023, 08:56 AM |
| Q2 2023 | 38 | $3.07B | +$271M | -$357M | -$86.2M | UHS, THC, VTRS, SNY, WBA | 13F-HR | 8/14/2023, 09:26 AM |
| Q1 2023 | 40 | $2.93B | +$387M | -$481M | -$94.4M | SNY, UHS, THC, WBA, VTRS | 13F-HR | 5/15/2023, 09:06 AM |
| Q4 2022 | 38 | $2.86B | +$425M | -$775M | -$350M | SNY, UHS, VTRS, THC, WBA | 13F-HR | 2/14/2023, 09:01 AM |
| Q3 2022 | 42 | $2.99B | +$983M | -$247M | +$736M | SNY, VTRS, UHS, SRPT, THC | 13F-HR | 11/14/2022, 09:37 AM |
| Q2 2022 | 40 | $2.3B | +$476M | -$653M | -$177M | VTRS, SNY, ZBH, SRPT, BMRN | 13F-HR | 8/15/2022, 08:55 AM |
| Q1 2022 | 37 | $2.76B | +$768M | -$487M | +$282M | VTRS, UHS, SNY, ZBH, GILD | 13F-HR | 5/16/2022, 08:39 AM |
| Q4 2021 | 36 | $2.59B | +$587M | -$597M | -$10M | VTRS, UHS, MRK, SNY, WBA | 13F-HR | 2/14/2022, 09:33 AM |
| Q3 2021 | 34 | $2.69B | +$615M | -$375M | +$240M | UHS, WBA, THC, VTRS, SNY | 13F-HR | 11/15/2021, 09:03 AM |
| Q2 2021 | 30 | $2.55B | +$541M | -$678M | -$138M | THC, WBA, VTRS, HCA, BKD | 13F-HR | 8/16/2021, 08:52 AM |
| Q1 2021 | 31 | $2.52B | +$595M | -$656M | -$61.7M | CHNG, WBA, UHS, VTRS, THC | 13F-HR | 5/17/2021, 08:49 AM |
| Q4 2020 | 28 | $2.43B | +$682M | -$481M | +$201M | CHNG, VTRS, UHS, ALXN, HCA | 13F-HR | 2/16/2021, 08:33 AM |
| Q3 2020 | 35 | $1.9B | +$448M | -$287M | +$161M | CHNG, MYL, ALXN, PRGO, UHS | 13F-HR/A | 11/16/2020, 04:51 PM |
| Q3 2020 | 35 | $1.9B | +$447M | -$287M | +$160M | CHNG, MYL, ALXN, PRGO, UHS | 13F-HR | 11/16/2020, 08:39 AM |
| Q2 2020 | 30 | $1.75B | +$439M | -$598M | -$159M | CHNG, MYL, ALXN, ALKS, PRGO | 13F-HR | 8/14/2020, 08:25 AM |
| Q1 2020 | 29 | $1.67B | +$775M | -$669M | +$106M | ALXN, CHNG, MYL, GSK, UHS | 13F-HR | 5/15/2020, 08:52 AM |
| Q4 2019 | 28 | $1.93B | +$281M | -$461M | -$180M | AGN, MYL, BIIB, GILD, THC | 13F-HR | 2/14/2020, 09:22 AM |
| Q3 2019 | 32 | $1.76B | +$453M | -$350M | +$103M | AGN, MYL, PRGO, BKD, DVA | 13F-HR | 11/14/2019, 09:15 AM |
| Q2 2019 | 28 | $1.71B | +$433M | -$369M | +$64.3M | AGN, MYL, DVA, PRGO, BKD | 13F-HR | 8/14/2019, 09:16 AM |
| Q1 2019 | 27 | $1.72B | +$432M | -$809M | -$378M | AGN, MYL, PRGO, GBT, BIIB | 13F-HR | 5/15/2019, 09:45 AM |
| Q4 2018 | 32 | $1.85B | +$623M | -$250M | +$374M | TSRO, MYL, AGN, UHS, MCK | 13F-HR | 2/14/2019, 10:17 AM |
| Q3 2018 | 25 | $1.76B | +$259M | -$719M | -$460M | AGN, HCA, MYL, TSRO, UHS | 13F-HR | 11/14/2018, 09:55 AM |
| Q2 2018 | 30 | $2.14B | +$418M | -$395M | +$22.6M | AGN, HCA, BIIB, GHDX, TSRO | 13F-HR | 8/14/2018, 09:23 AM |
| Q1 2018 | 32 | $2.04B | +$765M | -$473M | +$292M | SHPG, NKTR, AGN, BIIB, HCA | 13F-HR | 5/15/2018, 08:48 AM |
| Q4 2017 | 31 | $1.53B | +$537M | -$387M | +$150M | NKTR, HCA, MYL, AGN, UHS | 13F-HR | 2/14/2018, 10:22 AM |
| Q3 2017 | 22 | $1.2B | +$360M | -$807M | -$447M | NKTR, THC, MYL, PRGO, GHDX | 13F-HR | 11/14/2017, 11:21 AM |
| Q2 2017 | 31 | $1.64B | +$272M | -$468M | -$196M | TEVA, MYL, GILD, NKTR, AGN | 13F-HR | 8/14/2017, 11:18 AM |
| Q1 2017 | 30 | $1.69B | +$217M | -$376M | -$159M | TEVA, MYL, GILD, NKTR, AGN | 13F-HR | 5/15/2017, 11:17 AM |
| Q4 2016 | 34 | $1.73B | +$558M | -$309M | +$249M | TEVA, MYL, AGN, GILD, PRGO | Restatement | 3/16/2017, 09:19 AM |
| Q3 2016 | 33 | $1.62B | +$292M | -$498M | -$206M | TEVA, MYL, PRGO, GILD, ENDPQ | 13F-HR | 11/14/2016, 11:20 AM |
| Q2 2016 | 44 | $1.72B | +$616M | -$514M | +$102M | TEVA, MYL, ENDPQ, CSII, MDCO | 13F-HR | 8/12/2016, 03:43 PM |
| Q1 2016 | 45 | $1.61B | +$592M | -$213M | +$378M | TEVA, MYL, MDCO, BKD, NUVA | 13F-HR | 5/13/2016, 04:00 PM |
| Q4 2015 | 40 | $1.36B | +$387M | -$318M | +$69.6M | TEVA, GHDX, MDCO, LIVN, AZN | 13F-HR | 2/12/2016, 08:17 AM |
| Q3 2015 | 43 | $1.17B | +$285M | -$173M | +$112M | TEVA, MDCO, AZN, CYBX, MYL | 13F-HR | 11/13/2015, 10:37 AM |
| Q2 2015 | 39 | $1.24B | +$384M | -$287M | +$97.3M | TEVA, AZN, MASI, MDCO, ESRX | 13F-HR | 8/14/2015, 10:07 AM |
| Q1 2015 | 36 | $1.18B | +$282M | -$388M | -$107M | TEVA, MASI, MDCO, GHDX, ESRX | 13F-HR | 5/15/2015, 11:09 AM |
| Q4 2014 | 38 | $1.2B | +$334M | -$272M | +$62M | TEVA, MASI, GSK, GHDX, CNMD | Restatement | 5/13/2015, 11:50 AM |
| Q3 2014 | 35 | $991M | +$343M | -$498M | -$155M | TEVA, MYL, MASI, GHDX, GSK | 13F-HR | 11/14/2014, 10:32 AM |
| Q2 2014 | 39 | $1.21B | +$335M | -$218M | +$117M | TEVA, V107SC, DGX, CYH, CNMD | 13F-HR | 8/14/2014, 10:03 AM |
| Q1 2014 | 38 | $1.04B | +$316M | -$370M | -$53.5M | TEVA, V107SC, THC, DGX, CNMD | 13F-HR | 5/15/2014, 10:28 AM |
| Q4 2013 | 35 | $1.04B | $0 | $0 | TEVA, MYL, V107SC, HCA, CNMD | 13F-HR | 2/14/2014, 07:55 AM |